Remove Advisory Remove Capital Raising Remove Retail
article thumbnail

Intrepid Expands its Consumer Practice with Dominic Rispoli Joining to Lead its Lifestyle Brands Practice

Intrepid Banker Insights

Dominic brings over 30 years of experience, having successfully completed numerous M&A and capital raising transactions for founder-owned businesses, private equity portfolio companies, and public companies across a wide range of consumer sectors. Lifestyle Brands is a cornerstone practice for Intrepid.

IT 52
article thumbnail

How Merchant Banks Help Businesses Grow and Succeed

Razorpay

Regular individuals have retail banks. Some merchant banks may be affiliated with other retail or investment banks, but this specialized branch of banking does not provide services to the general public. Huge corporations have investment banks. What do medium to big-sized businesses have? The answer: Merchant banks.

Banking 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What is Private Banking and How Does It Work?

Razorpay

Unlike retail banking, which caters to the general public, private banking focuses on delivering banking services for affluent individuals and businesses. It also offers investment banking services such as equity underwriting, mergers and acquisitions, debt restructuring, and capital raising.

Banking 52
article thumbnail

The essential guide to raising private equity

Growth Business

We do that by supporting brands with local knowledge, marketing expertise and logistics and our role is to work with a global brand to push their products to the right retailer. The real difference compared to the UK is the advancements of retailers. That’s not to say that it wasn’t stressful at times!

article thumbnail

Biotech Hedge Funds: A Match Made in Heaven

Mergers and Inquisitions

In technology, as a startup keeps raising capital, it normally does so at gradually higher valuations as its customers, users, and revenue grow. But in biotech, companies valuations often remain close to their total capital raised until much later in the process (i.e.,

Funds 64